A new study has shown that both in patients with multiple sclerosis (MS) and in healthy controls, dopamine inhibits production of IL-17 and IFN-γ by peripheral blood mononuclear cells. The finding adds to previous evidence for the potential benefit of dopaminergic drugs in MS.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Dopaminergic stimulation leads B-cell infiltration into the central nervous system upon autoimmunity
Journal of Neuroinflammation Open Access 17 December 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hemmer, B., Nessler, S., Zhou, D., Kieseier, B. & Hartung, H. P. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol. 2, 201–211 (2006).
Tzartos, J. S. et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172, 146–155 (2008).
Melnikov, M., Belousova, O., Murugin, V., Pashenkov, M. & Boyko, A. The role of dopamine in modulation of Th-17 immune response in multiple sclerosis. J. Neuroimmunol. 292, 97–101 (2016).
Cosentino, M. & Marino, F. Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks? J. Neuroimmune Pharmacol. 8, 163–179 (2013).
Beaulieu, J.-M. & Gainetdinov, R. R. The physiology, signalling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63, 182–217 (2011).
Sarkar, C., Basu, B., Chakroborty, D., Dasgupta, P. S. & Basu, S. The immunoregulatory role of dopamine: an update. Brain Behav. Immun. 24, 525–528 (2010).
Levite, M. in Nerve-Driven Immunity — Neurotransmitters and Neuropeptides in the Immune System Ch. 1 (ed. Levite, M.) 1–45 (Springer-Verlag, Wien, 2012).
Pacheco, R., Contreras, F. & Zouali, M. The dopaminergic system in autoimmune diseases. Front. Immunol. 5, 117 (2014).
Cosentino, M. et al. Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 109, 632–642 (2007).
Venken, K., Hellings, N., Liblau, R. & Stinissen, P. Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol. Med. 16, 58–68 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Marino, F., Cosentino, M. Repurposing dopaminergic drugs for MS — the evidence mounts. Nat Rev Neurol 12, 191–192 (2016). https://doi.org/10.1038/nrneurol.2016.33
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2016.33
This article is cited by
-
D1 Receptor Blockade Suppresses the Function of Th-17 Cells in Multiple Sclerosis
Neuroscience and Behavioral Physiology (2022)
-
Perspectives for Dopaminergic Therapy in Multiple Sclerosis
Neuroscience and Behavioral Physiology (2022)
-
Dopaminergic stimulation leads B-cell infiltration into the central nervous system upon autoimmunity
Journal of Neuroinflammation (2021)
-
Dopaminergic Pathways in Obesity-Associated Inflammation
Journal of Neuroimmune Pharmacology (2020)
-
Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease
Journal of Neuroimmune Pharmacology (2020)